SNX-5422 is an investigational drug.
There have been 16 clinical trials for SNX-5422.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2006.
The most common disease conditions in clinical trials are Neoplasms, Lymphoma, and Hematologic Neoplasms. The leading clinical trial sponsors are Esanex Inc., Serenex, Inc., and National Cancer Institute (NCI).